{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T23:48:37Z","timestamp":1740181717063,"version":"3.37.3"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Egypt Heart J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Coronavirus disease of 2019 (COVID-19) is associated with venous thromboembolism (VTE), not only during hospitalization but also after discharge, raising concerns about anticoagulant (AC) use for post-discharge COVID-19 patients. We aimed to systematically review the current literature on the possible benefits or risks regarding extended thromboprophylaxis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Main body<\/jats:title>\n                <jats:p>We searched related databases from December 1, 2019, to October 6, 2022, including studies on the necessity, duration, and selection of the ideal AC regarding extended thromboprophylaxis for post-discharge COVID-19 patients. The screening of the selected databases led to 18 studies and 19 reviews and guidelines. Studies included 52,927 hospitalized COVID-19 patients, with 19.25% receiving extended thromboprophylaxis. VTE events ranging from 0 to 8.19% (median of 0.7%) occurred in a median follow-up of 49.5 days. All included studies and guidelines, except four studies, recommended post-discharge prophylaxis after an individual risk assessment indicating high thrombotic and low bleeding risk. Studies used risk assessment models (RAMs), clinical evaluation, and laboratory data to identify COVID-19 patients with a high risk of VTE. IMPROVE-DD was the most recommended RAM. Direct oral anticoagulants (DOACs) and low molecular weight heparins (LMWHs) were the most used AC classes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Post-discharge prophylaxis for COVID-19 patients is recommended after an individual assessment. The IMPROVE-DD model can help predict VTE risk. After distinguishing patients who need post-discharge AC therapy, DOACs for 30\u201335 days and LMWHs for 40\u201345 days can be the drug of choice. Further studies, particularly the results of the ongoing randomized controlled trials (RCTs), are required. Also, to properly handle such patients, every physician should consider lifestyle modification in addition to pharmacological treatment for post-discharge VTE prophylaxis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s43044-023-00400-2","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T16:48:58Z","timestamp":1692377338000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A systematic review on post-discharge venous thromboembolism prophylaxis in patients with COVID-19"],"prefix":"10.1186","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8383-6676","authenticated-orcid":false,"given":"Reza","family":"Amani-Beni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3701-3572","authenticated-orcid":false,"given":"Mohammad","family":"Kermani-Alghoraishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5269-0061","authenticated-orcid":false,"given":"Bahar","family":"Darouei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9173-3944","authenticated-orcid":false,"given":"Christopher M.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,18]]},"reference":[{"key":"400_CR1","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang C-L (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579:270\u2013273","journal-title":"Nature"},{"key":"400_CR2","unstructured":"WHO Coronavirus (COVID-19) Dashboard (1 November 2022) WHO. https:\/\/covid19.who.int\/"},{"key":"400_CR3","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1002\/phar.2465","volume":"40","author":"PP Dobesh","year":"2020","unstructured":"Dobesh PP, Trujillo TC (2020) Coagulopathy, venous thromboembolism, and anticoagulation in patients with COVID-19. Pharmacotherapy 40:1130\u20131151. https:\/\/doi.org\/10.1002\/phar.2465","journal-title":"Pharmacotherapy"},{"key":"400_CR4","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/00003246-198207000-00006","volume":"10","author":"JF Cade","year":"1982","unstructured":"Cade JF (1982) High risk of the critically ill for venous thromboembolism. Crit Care Med 10:448\u2013450","journal-title":"Crit Care Med"},{"issue":"07","key":"400_CR5","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1055\/s-0040-1715456","volume":"46","author":"A Di Minno","year":"2020","unstructured":"Di Minno A, Ambrosino P, Calcaterra I, Di Minno MND (2020) COVID-19 and venous thromboembolism: a meta-analysis of literature studies. Semin Thromb Hemost 46(07):763\u2013771. https:\/\/doi.org\/10.1055\/s-0040-1715456","journal-title":"Semin Thromb Hemost"},{"key":"400_CR6","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.chest.2020.11.005","volume":"159","author":"D Jim\u00e9nez","year":"2021","unstructured":"Jim\u00e9nez D, Garc\u00eda-Sanchez A, Rali P, Muriel A, Bikdeli B, Ruiz-Artacho P, Le Mao R, Rodr\u00edguez C, Hunt BJ, Monreal M (2021) Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis. Chest 159:1182\u20131196","journal-title":"Chest"},{"key":"400_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00459","author":"MJ Nasiri","year":"2020","unstructured":"Nasiri MJ, Haddadi S, Tahvildari A, Farsi Y, Arbabi M, Hasanzadeh S, Jamshidi P, Murthi M, Mirsaeidi M (2020) COVID-19 clinical characteristics, and sex-specific risk of mortality: systematic review and meta-analysis. Front Med. https:\/\/doi.org\/10.3389\/fmed.2020.00459","journal-title":"Front Med"},{"key":"400_CR8","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.thromres.2021.11.029","volume":"209","author":"M Zuin","year":"2022","unstructured":"Zuin M, Engelen MM, Barco S, Spyropoulos AC, Vanassche T, Hunt BJ, Vandenbriele C, Verhamme P, Kucher N, Rashidi F (2022) Incidence of venous thromboembolic events in COVID-19 patients after hospital discharge: a systematic review and meta-analysis. Thromb Res 209:94\u201398","journal-title":"Thromb Res"},{"key":"400_CR9","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1055\/a-1913-4377","volume":"6","author":"EM Mansory","year":"2022","unstructured":"Mansory EM, Abu-Farhaneh M, Iansavitchene A, Lazo-Langner A (2022) Venous and arterial thrombosis in ambulatory and discharged COVID-19 Patients: a systematic review and meta-analysis. TH Open 6:e276\u2013e282","journal-title":"TH Open"},{"key":"400_CR10","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1182\/blood.2020007938","volume":"136","author":"R Patell","year":"2020","unstructured":"Patell R, Bogue T, Koshy A, Bindal P, Merrill M, Aird WC, Bauer KA, Zwicker JI (2020) Postdischarge thrombosis and hemorrhage in patients with COVID-19. Blood 136:1342\u20131346","journal-title":"Blood"},{"key":"400_CR11","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(21)02392-8","volume":"399","author":"E Ramacciotti","year":"2022","unstructured":"Ramacciotti E, Agati LB, Calderaro D, Aguiar VCR, Spyropoulos AC, de Oliveira CCC, Dos Santos JL, Volpiani GG, Sobreira ML, Joviliano EE (2022) Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet 399:50\u201359","journal-title":"Lancet"},{"key":"400_CR12","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1182\/bloodadvances.2021005945","volume":"6","author":"A Cuker","year":"2022","unstructured":"Cuker A, Tseng EK, Nieuwlaat R, Angchaisuksiri P, Blair C, Dane K, Davila J, DeSancho MT, Diuguid D, Griffin DO, Kahn SR, Klok FA, Lee AI, Neumann I, Pai A, Righini M, Sanfilippo KM, Siegal D, Skara M, Terrell DR, Touri K, Akl EA, Al Jabiri RN, Al Jabiri YN, Barbara AM, Bognanni A, Bou Akl I, Boulos M, Brignardello-Petersen R, Charide R, Chan M, Colunga-Lozano LE, Dearness K, Darzi AJ, Hussein H, Karam SG, Kolb P, Mansour R, Morgano GP, Morsi RZ, Muti-Sch\u00fcnemann G, Nadim MK, Noori A, Philip BA, Piggott T, Qiu Y, Benitez YR, Sch\u00fcnemann F, Stevens A, Solo K, Wiercioch W, Mustafa RA, Sch\u00fcnemann HJ (2022) American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis. Blood Adv 6:664\u2013671. https:\/\/doi.org\/10.1182\/bloodadvances.2021005945","journal-title":"Blood Adv"},{"key":"400_CR13","volume-title":"Will the COVID-19 pandemic end with the Delta and Omicron variants?","author":"C Wang","year":"2022","unstructured":"Wang C, Han J (2022) Will the COVID-19 pandemic end with the Delta and Omicron variants? Springer"},{"key":"400_CR14","doi-asserted-by":"crossref","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg 88:105906","journal-title":"Int J Surg"},{"key":"400_CR15","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, Tugwell P (2000) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Oxford"},{"key":"400_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2458-13-154","volume":"13","author":"R Herzog","year":"2013","unstructured":"Herzog R, \u00c1lvarez-Pasquin M, D\u00edaz C, Del Barrio JL, Estrada JM, Gil \u00c1 (2013) Are healthcare workers\u2019 intentions to vaccinate related to their knowledge, beliefs and attitudes? A systematic review. BMC Public Health 13:1\u201317","journal-title":"BMC Public Health"},{"key":"400_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1\u201312","journal-title":"Control Clin Trials"},{"key":"400_CR18","unstructured":"Viswanathan M, Ansari M, Berkman N, Chang S, Hartling L, McPheeters M, Treadwell J (2012) Assessing the risk of bias of individual studies in systematic reviews of health care interventions. Agency for healthcare research and quality methods guide for comparative effectiveness reviews. AHRQ Methods for Effective Health Care"},{"issue":"12","key":"400_CR19","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.4065\/81.12.1567","volume":"81","author":"ME Falagas","year":"2006","unstructured":"Falagas ME, Siempos II, Bliziotis IA, Panos GZ (2006) Impact of initial discordant treatment with \u03b2-lactam antibiotics on clinical outcomes in adults with pneumococcal pneumonia: a systematic review. Mayo Clin Proc 81(12):1567\u20131574. https:\/\/doi.org\/10.4065\/81.12.1567","journal-title":"Mayo Clin Proc"},{"key":"400_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.13633","author":"JY Tan","year":"2021","unstructured":"Tan JY, Tan CW, Wong WH, Cheong MA, Lee LH, Kalimuddin S, Low JGH, Ng HJ (2021) Post-hospitalization venous thromboembolism in COVID-19 patients: evidence against routine post-hospitalization prophylactic anticoagulation. Int J Lab Hematol. https:\/\/doi.org\/10.1111\/ijlh.13633","journal-title":"Int J Lab Hematol"},{"key":"400_CR21","unstructured":"NICE (2022) COVID-19 rapid guideline: managing COVID-19. https:\/\/www.guidelines.co.uk\/infection\/nice-managing-covid-19-guideline\/455939.article. Accessed 10 July 2022"},{"key":"400_CR22","doi-asserted-by":"publisher","first-page":"e2135397","DOI":"10.1001\/jamanetworkopen.2021.35397","volume":"4","author":"P Li","year":"2021","unstructured":"Li P, Zhao W, Kaatz S, Latack K, Schultz L, Poisson L (2021) Factors associated with risk of postdischarge thrombosis in patients with COVID-19. JAMA Netw Open 4:e2135397. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.35397","journal-title":"JAMA Netw Open"},{"key":"400_CR23","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.thromres.2021.03.031","volume":"201","author":"K Stawiarski","year":"2021","unstructured":"Stawiarski K, Loutoo A, Velardi L, Zarich S (2021) D-dimer driven deep vein thrombosis prophylaxis strategy for hospitalized patients with COVID-19. Thromb Res 201:151\u2013153","journal-title":"Thromb Res"},{"key":"400_CR24","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.thromres.2020.12.001","volume":"198","author":"F Rashidi","year":"2021","unstructured":"Rashidi F, Barco S, Kamangar F, Heresi GA, Emadi A, Kaymaz C, Jansa P, Reis A, Rashidi A, Taghizadieh A (2021) Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: prospective results from a multi-center study. Thromb Res 198:135\u2013138","journal-title":"Thromb Res"},{"key":"400_CR25","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/rth2.12485","volume":"5","author":"H Eswaran","year":"2021","unstructured":"Eswaran H, Jarmul JA, Shaheen AW, Meaux D, Long T, Saccoccio D, Moll S (2021) Vascular thromboembolic events following COVID-19 hospital discharge: incidence and risk factors. Res Pract Thromb Haemost 5:292\u2013295. https:\/\/doi.org\/10.1002\/rth2.12485","journal-title":"Res Pract Thromb Haemost"},{"key":"400_CR26","doi-asserted-by":"crossref","first-page":"e0266944","DOI":"10.1371\/journal.pone.0266944","volume":"17","author":"AL Parks","year":"2022","unstructured":"Parks AL, Auerbach AD, Schnipper JL, Bertram A, Jeon SY, Boyle B, Fang MC, Gadrey SM, Siddiqui ZK, Brotman DJ (2022) Venous thromboembolism (VTE) prevention and diagnosis in COVID-19: practice patterns and outcomes at 33 hospitals. PLoS ONE 17:e0266944","journal-title":"PLoS ONE"},{"key":"400_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2021-002877","author":"HQ Ambel","year":"2021","unstructured":"Ambel HQ, Crespo-Robledo P, Juaristi KA, Plo-Seco I, Sim\u00f3n JJM, Fern\u00e1ndez EP, Encinas MP (2021) Effectiveness of antithrombotic prophylaxis in hospitalised patients with SARS-CoV-2 infection. Eur J Hosp Pharm. https:\/\/doi.org\/10.1136\/ejhpharm-2021-002877","journal-title":"Eur J Hosp Pharm"},{"key":"400_CR28","doi-asserted-by":"crossref","first-page":"e408","DOI":"10.1055\/a-1937-9692","volume":"06","author":"AC Spyropoulos","year":"2022","unstructured":"Spyropoulos AC, Crawford JM, Chen Y-W, Ashton V, Campbell AK, Milentijevic D, Peacock WF (2022) Occurrence of thromboembolic events and mortality among hospitalized COVID-19 patients: large observational cohort study of electronic health records. TH Open 06:e408","journal-title":"TH Open"},{"key":"400_CR29","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/rth2.12486","volume":"5","author":"AC Spyropoulos","year":"2021","unstructured":"Spyropoulos AC, Cohen SL, Gianos E, Kohn N, Giannis D, Chatterjee S, Goldin M, Lesser M, Coppa K, Hirsch JS (2021) Validation of the IMPROVE-DD risk assessment model for venous thromboembolism among hospitalized patients with COVID-19. Res Pract Thrombos Haemost 5:296\u2013300","journal-title":"Res Pract Thrombos Haemost"},{"key":"400_CR30","doi-asserted-by":"publisher","DOI":"10.1177\/10600280211064306","author":"LA Courtney","year":"2022","unstructured":"Courtney LA, Trujillo TC, Saseen JJ, Wright G, Palkimas S (2022) Evaluation of the clinical impact of thromboprophylaxis in patients with COVID-19 following hospital discharge. Ann Pharmacother. https:\/\/doi.org\/10.1177\/10600280211064306","journal-title":"Ann Pharmacother"},{"key":"400_CR31","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1007\/s11239-021-02504-5","volume":"52","author":"M Goldin","year":"2021","unstructured":"Goldin M, Lin SK, Kohn N, Qiu M, Cohen SL, Barish MA, Gianos E, Diaz A, Richardson S, Giannis D (2021) External validation of the IMPROVE-DD risk assessment model for venous thromboembolism among inpatients with COVID-19. J Thromb Thrombol 52:1032\u20131035","journal-title":"J Thromb Thrombol"},{"key":"400_CR32","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1182\/blood.2020010529","volume":"137","author":"D Giannis","year":"2021","unstructured":"Giannis D, Allen SL, Tsang J, Flint S, Pinhasov T, Williams S, Tan G, Thakur R, Leung C, Snyder M, Bhatia C, Garrett D, Cotte C, Isaacs S, Gugerty E, Davidson A, Marder GS, Schnitzer A, Goldberg B, McGinn T, Davidson KW, Barish MA, Qiu M, Zhang M, Goldin M, Matsagkas M, Arnaoutoglou E, Spyropoulos AC (2021) Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry. Blood 137:2838\u20132847. https:\/\/doi.org\/10.1182\/blood.2020010529","journal-title":"Blood"},{"key":"400_CR33","doi-asserted-by":"publisher","first-page":"6230","DOI":"10.1182\/bloodadvances.2020003349","volume":"4","author":"R Salisbury","year":"2020","unstructured":"Salisbury R, Iotchkova V, Jaafar S, Morton J, Sangha G, Shah A, Untiveros P, Curry N, Shapiro S (2020) Incidence of symptomatic, image-confirmed venous thromboembolism following hospitalization for COVID-19 with 90-day follow-up. Blood Adv 4:6230\u20136239. https:\/\/doi.org\/10.1182\/bloodadvances.2020003349","journal-title":"Blood Adv"},{"key":"400_CR34","unstructured":"NIH (2022) Antithrombotic therapy in patients with COVID-19. https:\/\/www.covid19treatmentguidelines.nih.gov\/. Accessed 26 Sept 2022"},{"key":"400_CR35","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11239-022-02643-3","volume":"54","author":"GD Barnes","year":"2022","unstructured":"Barnes GD, Burnett A, Allen A, Ansell J, Blumenstein M, Clark NP, Crowther M, Dager WE, Deitelzweig SB, Ellsworth S (2022) Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum. J Thromb Thrombol 54:197","journal-title":"J Thromb Thrombol"},{"key":"400_CR36","doi-asserted-by":"crossref","first-page":"916156","DOI":"10.3389\/fcvm.2022.916156","volume":"9","author":"LJ Motloch","year":"2022","unstructured":"Motloch LJ, Jirak P, Mirna M, Fiedler L, Davtyan PA, Lakman IA, Gareeva DF, Tyurin AV, Gumerov RM, Matskeplishvili ST (2022) Early antithrombotic post-discharge therapy using prophylactic DOAC or dipyridamole improves long-term survival and cardiovascular outcomes in hospitalized COVID-19 survivors. Front Cardiovasc Med 9:916156","journal-title":"Front Cardiovasc Med"},{"key":"400_CR37","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.thromres.2020.12.001","volume":"198","author":"F Rashidi","year":"2021","unstructured":"Rashidi F, Barco S, Kamangar F, Heresi GA, Emadi A, Kaymaz C, Jansa P, Reis A, Rashidi A, Taghizadieh A, Rezaeifar P, Moghimi M, Ghodrati S, Mozafari A, Foumani AA, Tahamtan O, Rafiee E, Abbaspour Z, Khodadadi K, Alamdari G, Boodaghi Y, Rezaei M, Muhammadi MJ, Abbasi M, Movaseghi F, Koohi A, Shakourzad L, Ebrahimi F, Radvar S, Amoozadeh M, Fereidooni F, Naseari H, Movalled K, Ghorbani O, Ansarin K (2021) Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: Prospective results from a multi-center study. Thromb Res 198:135\u2013138. https:\/\/doi.org\/10.1016\/j.thromres.2020.12.001","journal-title":"Thromb Res"},{"key":"400_CR38","volume-title":"Hospitalized COVID-19 patients and venous thromboembolism: a perfect storm","author":"AC Spyropoulos","year":"2020","unstructured":"Spyropoulos AC, Weitz JI (2020) Hospitalized COVID-19 patients and venous thromboembolism: a perfect storm. Am Heart Assoc"},{"key":"400_CR39","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1055\/s-0040-1705137","volume":"4","author":"AC Spyropoulos","year":"2020","unstructured":"Spyropoulos AC, Lipardi C, Xu J, Peluso C, Spiro TE, De Sanctis Y, Barnathan ES, Raskob GE (2020) Modified IMPROVE VTE risk score and elevated D-dimer identify a high venous thromboembolism risk in acutely ill medical population for extended thromboprophylaxis. TH open 4:e59\u2013e65","journal-title":"TH open"},{"issue":"1371\u20131381","key":"400_CR40","first-page":"e1374","volume":"9","author":"S Tsaplin","year":"2021","unstructured":"Tsaplin S, Schastlivtsev I, Zhuravlev S, Barinov V, Lobastov K, Caprini JA (2021) The original and modified Caprini score equally predicts venous thromboembolism in COVID-19 patients. J Vasc Surg Venous Lymphat Disord 9(1371\u20131381):e1374","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"key":"400_CR41","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1016\/j.jacc.2020.04.031","volume":"75","author":"B Bikdeli","year":"2020","unstructured":"Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, Nigoghossian CD, Ageno W, Madjid M, Guo Y (2020) COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol 75:2950\u20132973","journal-title":"J Am Coll Cardiol"},{"issue":"04","key":"400_CR42","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1055\/s-0041-1727284","volume":"47","author":"MM Engelen","year":"2021","unstructured":"Engelen MM, Vandenbriele C, Balthazar T, Claeys E, Gunst J, Guler I, Jacquemin M, Janssens S, Lorent N, Liesenborghs L, Peerlinck K, Pieters G, Rex S, Sinonquel P, Van der Linden L, Van Laer C, Vos R, Wauters J, Wilmer A, Verhamme P, Vanassche T (2021) Venous thromboembolism in patients discharged after COVID-19 hospitalization. Semin Thromb Hemost 47(04):362\u2013371. https:\/\/doi.org\/10.1055\/s-0041-1727284","journal-title":"Semin Thromb Hemost"},{"key":"400_CR43","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.tracli.2020.09.004","volume":"27","author":"M Chekkal","year":"2020","unstructured":"Chekkal M, Deba T, Hadjali S, Lamara H, Oulaa H, Zouai K, Hariti G (2020) Prevention and treatment of COVID-19-associated hypercoagulability: recommendations of the Algerian society of transfusion and hemobiology. Transfus Clin Biol 27:203\u2013206","journal-title":"Transfus Clin Biol"},{"key":"400_CR44","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1111\/jth.14929","volume":"18","author":"AC Spyropoulos","year":"2020","unstructured":"Spyropoulos AC, Levy JH, Ageno W, Connors JM, Hunt BJ, Iba T, Levi M, Samama CM, Giannis D (2020) Scientific and standardization committee communication: clinical guidance on the diagnosis, prevention and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost 18:1859","journal-title":"J Thromb Haemost"},{"key":"400_CR45","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.cmi.2022.02.018","volume":"28","author":"D Yelin","year":"2022","unstructured":"Yelin D, Moschopoulos CD, Margalit I, Gkrania-Klotsas E, Landi F, Stahl J-P, Yahav D (2022) ESCMID rapid guidelines for assessment and management of long COVID. Clin Microbiol Infect 28:955","journal-title":"Clin Microbiol Infect"},{"key":"400_CR46","first-page":"167","volume":"18","author":"M Marietta","year":"2020","unstructured":"Marietta M, Ageno W, Artoni A, De Candia E, Gresele P, Marchetti M, Marcucci R, Tripodi A (2020) COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET). Blood Transfus 18:167","journal-title":"Blood Transfus"},{"key":"400_CR47","first-page":"2838","volume":"137","author":"D Giannis","year":"2021","unstructured":"Giannis D, Allen SL, Tsang J, Flint S, Pinhasov T, Williams S, Tan G, Thakur R, Leung C, Snyder M (2021) Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry. Blood J Am Soc Hematol 137:2838\u20132847","journal-title":"Blood J Am Soc Hematol"},{"key":"400_CR48","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.htct.2020.06.001","volume":"42","author":"FA Orsi","year":"2020","unstructured":"Orsi FA, De Paula EV, Santos FdO, Teruchkin MM, Camp\u00ealo DHC, Mello TT, Chindamo MC, Macedo AVS, Rocha AT, Ramacciotti E (2020) Guidance on diagnosis, prevention and treatment of thromboembolic complications in COVID-19: a position paper of the Brazilian Society of Thrombosis and Hemostasis and the Thrombosis and Hemostasis Committee of the Brazilian Association of Hematology, Hemotherapy and Cellular Therapy. Hematol Transfus Cell Therapy 42:300\u2013308","journal-title":"Hematol Transfus Cell Therapy"},{"key":"400_CR49","doi-asserted-by":"publisher","DOI":"10.1024\/0301-1526\/a000885","author":"B Linnemann","year":"2020","unstructured":"Linnemann B, Bauersachs R, Grebe M, Klamroth R, M\u00fcller O, Schellong S, Lichtenberg M (2020) Venous thromboembolism in patients with COVID-19 (SARS-CoV-2 infection)\u2013a position paper of the German Society of Angiology (DGA). Vasa. https:\/\/doi.org\/10.1024\/0301-1526\/a000885","journal-title":"Vasa"},{"key":"400_CR50","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1111\/jth.15808","volume":"20","author":"S Schulman","year":"2022","unstructured":"Schulman S, Sholzberg M, Spyropoulos AC, Zarychanski R, Resnick HE, Bradbury CA, Broxmeyer L, Connors JM, Falanga A, Iba T (2022) ISTH guidelines for antithrombotic treatment in COVID-19. J Thromb Haemost 20:2214\u20132225","journal-title":"J Thromb Haemost"},{"key":"400_CR51","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/21548331.2020.1772639","volume":"48","author":"RA Watson","year":"2020","unstructured":"Watson RA, Johnson DM, Dharia RN, Merli GJ, Doherty JU (2020) Anti-coagulant and anti-platelet therapy in the COVID-19 patient: a best practices quality initiative across a large health system. Hosp Pract 48:169\u2013179","journal-title":"Hosp Pract"},{"key":"400_CR52","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1055\/s-0040-1715798","volume":"120","author":"GT Gerotziafas","year":"2020","unstructured":"Gerotziafas GT, Catalano M, Colgan M-P, Pecsvarady Z, Wautrecht JC, Fazeli B, Olinic D-M, Farkas K, Elalamy I, Falanga A (2020) Guidance for the management of patients with vascular disease or cardiovascular risk factors and COVID-19: position paper from VAS-European independent foundation in angiology\/vascular medicine. Thromb Haemost 120:1597\u20131628","journal-title":"Thromb Haemost"},{"key":"400_CR53","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri3345","volume":"13","author":"B Engelmann","year":"2013","unstructured":"Engelmann B, Massberg S (2013) Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 13:34\u201345","journal-title":"Nat Rev Immunol"},{"key":"400_CR54","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1161\/CIRCULATIONAHA.120.048488","volume":"142","author":"L Nicolai","year":"2020","unstructured":"Nicolai L, Leunig A, Brambs S, Kaiser R, Weinberger T, Weigand M, Muenchhoff M, Hellmuth JC, Ledderose S, Schulz H (2020) Immunothrombotic dysregulation in COVID-19 pneumonia is associated with respiratory failure and coagulopathy. Circulation 142:1176\u20131189","journal-title":"Circulation"},{"key":"400_CR55","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1007\/s42399-020-00426-6","volume":"2","author":"C-S Hu","year":"2020","unstructured":"Hu C-S (2020) Analysis of COVID-19 cases and public measures in China. SN Compr Clin Med 2:1306\u20131312","journal-title":"SN Compr Clin Med"},{"key":"400_CR56","doi-asserted-by":"crossref","first-page":"e025914","DOI":"10.1161\/JAHA.122.025914","volume":"11","author":"VM Vaughn","year":"2022","unstructured":"Vaughn VM, Ratz D, McLaughlin ES, Horowitz JK, Flanders SA, Middleton EA, Grant PJ, Kaatz S, Barnes GD (2022) Eligibility for posthospitalization venous thromboembolism prophylaxis in hospitalized patients with COVID-19: a retrospective cohort study. J Am Heart Assoc 11:e025914","journal-title":"J Am Heart Assoc"},{"key":"400_CR57","doi-asserted-by":"crossref","first-page":"100096","DOI":"10.1016\/j.tru.2021.100096","volume":"6","author":"B Tholin","year":"2022","unstructured":"Tholin B, Fiskvik H, Tveita A, Tsykonova G, Opperud H, Busterud K, Mpinganzima C, Garabet L, Ahmed J, Stavem K (2022) Thromboembolic complications during and after hospitalization for COVID-19: incidence, risk factors and thromboprophylaxis. Thrombosis Update 6:100096","journal-title":"Thrombosis Update"},{"key":"400_CR58","first-page":"1","volume":"34","author":"C Ferreira","year":"2022","unstructured":"Ferreira C, da Rocha AP, Nunes S, de Oliveira MS, Prado CCL, Cristina V, Veiga C, Vidal \u00c1T, Xavier RM, Zavascki AP (2022) Brazilian Guidelines for the pharmacological treatment of patients hospitalized with COVID-19. Rev Bras Ter Intensiva 34:1\u201312","journal-title":"Rev Bras Ter Intensiva"},{"key":"400_CR59","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s40256-020-00446-6","volume":"20","author":"G Patti","year":"2020","unstructured":"Patti G, Lio V, Cavallari I, Gragnano F, Riva L, Calabr\u00f2 P, Di Pasquale G, Pengo V, Rubboli A (2020) Questions and answers on practical thrombotic issues in SARS-CoV-2 infection: a guidance document from the italian working group on atherosclerosis, thrombosis and vascular biology. Am J Cardiovasc Drugs 20:559\u2013570","journal-title":"Am J Cardiovasc Drugs"},{"key":"400_CR60","unstructured":"SIGN (2020) COVID-19 position statement: The prevention and management of thromboembolism in hospitalised patients with COVID-19-related disease. https:\/\/www.sign.ac.uk\/media\/1691\/sg_prevention_of_thromboembolism_in_hospitalised_patients.pdf. Accessed 16 Jul 2020"},{"key":"400_CR61","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.chest.2020.05.559","volume":"158","author":"LK Moores","year":"2020","unstructured":"Moores LK, Tritschler T, Brosnahan S, Carrier M, Collen JF, Doerschug K, Holley AB, Jimenez D, Le Gal G, Rali P (2020) Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report. Chest 158:1143\u20131163","journal-title":"Chest"},{"key":"400_CR62","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1055\/s-0040-1710019","volume":"120","author":"Z Zhai","year":"2020","unstructured":"Zhai Z, Li C, Chen Y, Gerotziafas G, Zhang Z, Wan J, Liu P, Elalamy I, Wang C (2020) Prevention and treatment of venous thromboembolism associated with coronavirus disease 2019 infection: a consensus statement before guidelines. Thromb Haemost 120:937\u2013948","journal-title":"Thromb Haemost"}],"container-title":["The Egyptian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-023-00400-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43044-023-00400-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-023-00400-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T06:05:12Z","timestamp":1700287512000},"score":1,"resource":{"primary":{"URL":"https:\/\/tehj.springeropen.com\/articles\/10.1186\/s43044-023-00400-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,18]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["400"],"URL":"https:\/\/doi.org\/10.1186\/s43044-023-00400-2","relation":{},"ISSN":["2090-911X"],"issn-type":[{"type":"electronic","value":"2090-911X"}],"subject":[],"published":{"date-parts":[[2023,8,18]]},"assertion":[{"value":"20 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"72"}}